Skip to main content

Press releases

Go back

Galimedix Therapeutics presents strong pharmacokinetic profile of next-generation oral Alzheimer’s candidate at AD/PD™ 2026

Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open Innovation

Galimedix Therapeutics to present promising pre-clinical data with next generation oral amyloid beta aggregation modulator at AD/PD™ 2026 Conference

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025

Progress in clinical development for Alzheimer’s and other indications: Galimedix Therapeutics successfully completes Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modulator

Galimedix Therapeutics publishes new data in peer-reviewed International Journal of Molecular Sciences demonstrating disease-modifying capability of GAL-201 in Alzheimer’s disease

Galimedix Therapeutics completes single ascending dose part of Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modulator

Galimedix Therapeutics presents further scientific data showing disease-modifying potential of oral GAL-201 in Alzheimer’s disease as well as beneficial effects on synaptic function and neuroimmunomodulation at AD/PD™ 2025

Galimedix Therapeutics to present positive pre-clinical data with amyloid beta aggregation modulator in development for oral Alzheimer’s disease treatment at AD/PD™ 2025 Conference

Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD

1
2
3